SEC Form 4 · accession 0001209191-15-080796
Revance Therapeutics, Inc. · RVNC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Arthur Peter Bertolino
Officer — EVP and Chief Medical Officer
Period of report
Nov 17, 2015
Accepted (ET)
Nov 17, 2015 · 9:45 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001479290
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 17, 2015 | S | 5,425 | $39.11 | D | 36,329 | D | |
| Common Stock | Nov 17, 2015 | S | 36 | $39.55 | D | 36,293 | D | |
| Common Stock | Nov 17, 2015 | S | 2,277 | $39.11 | D | 34,016 | D | |
| Common Stock | Nov 17, 2015 | S | 15 | $39.55 | D | 34,001 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The Reporting Person sold an aggregate of 5,461 shares of restricted stock to settle a personal tax liability in connection with the November 15, 2015 vesting of certain shares of restricted stock that the Reporting Person acquired pursuant to a grant dated September 2, 2014.
- F2The Reporting Person sold an aggregate of 2,292 shares of restricted stock to settle a personal tax liability in connection with the November 15, 2015 vesting of certain shares of restricted stock that the Reporting Person acquired pursuant to a grant dated January 28, 2015.